EMEA-000715-PIP05-13-M03

Key facts

Invented name
Otezla
Active substance
apremilast
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0398/2018
PIP number
EMEA-000715-PIP05-13-M03
Pharmaceutical form(s)
  • Tablet
  • Oral suspension
Condition(s) / indication(s)
Treatment of Behcet disease
Route(s) of administration
Oral use
Contact for public enquiries
Celgene Europe Limited

Tel.  +41 327298500
E-mail: medinfo.intl@celgene.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating